239 related articles for article (PubMed ID: 32512040)
1. The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer.
Mauri G; Arena S; Siena S; Bardelli A; Sartore-Bianchi A
Ann Oncol; 2020 Sep; 31(9):1135-1147. PubMed ID: 32512040
[TBL] [Abstract][Full Text] [Related]
2. Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.
Basourakos SP; Li L; Aparicio AM; Corn PG; Kim J; Thompson TC
Curr Med Chem; 2017; 24(15):1586-1606. PubMed ID: 27978798
[TBL] [Abstract][Full Text] [Related]
3. PARP Inhibitors in Colorectal Malignancies: A 2023 Update.
Skouteris N; Papageorgiou G
Rev Recent Clin Trials; 2024; 19(2):101-108. PubMed ID: 38058097
[TBL] [Abstract][Full Text] [Related]
4. Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer.
Catalano F; Borea R; Puglisi S; Boutros A; Gandini A; Cremante M; Martelli V; Sciallero S; Puccini A
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326540
[TBL] [Abstract][Full Text] [Related]
5. Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy.
Gourley C; Balmaña J; Ledermann JA; Serra V; Dent R; Loibl S; Pujade-Lauraine E; Boulton SJ
J Clin Oncol; 2019 Sep; 37(25):2257-2269. PubMed ID: 31050911
[TBL] [Abstract][Full Text] [Related]
6. DNA damage response pathways and cell cycle checkpoints in colorectal cancer: current concepts and future perspectives for targeted treatment.
Solier S; Zhang YW; Ballestrero A; Pommier Y; Zoppoli G
Curr Cancer Drug Targets; 2012 May; 12(4):356-71. PubMed ID: 22385513
[TBL] [Abstract][Full Text] [Related]
7. DNA damage response as a therapeutic target in gynecological cancers.
Leary A; Auguste A; Mesnage S
Curr Opin Oncol; 2016 Sep; 28(5):404-11. PubMed ID: 27455135
[TBL] [Abstract][Full Text] [Related]
8. The DNA Damaging Revolution: PARP Inhibitors and Beyond.
Yap TA; Plummer R; Azad NS; Helleday T
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():185-195. PubMed ID: 31099635
[TBL] [Abstract][Full Text] [Related]
9. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.
Lin PH; Chen M; Tsai LW; Lo C; Yen TC; Huang TY; Chen CK; Fan SC; Kuo SH; Huang CS
Cancer Sci; 2020 Apr; 111(4):1375-1384. PubMed ID: 31958182
[TBL] [Abstract][Full Text] [Related]
10. Exploiting DNA repair defects in colorectal cancer.
Reilly NM; Novara L; Di Nicolantonio F; Bardelli A
Mol Oncol; 2019 Apr; 13(4):681-700. PubMed ID: 30714316
[TBL] [Abstract][Full Text] [Related]
11. Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor.
Takagi M; Yoshida M; Nemoto Y; Tamaichi H; Tsuchida R; Seki M; Uryu K; Nishii R; Miyamoto S; Saito M; Hanada R; Kaneko H; Miyano S; Kataoka K; Yoshida K; Ohira M; Hayashi Y; Nakagawara A; Ogawa S; Mizutani S; Takita J
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059438
[TBL] [Abstract][Full Text] [Related]
12. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
13. Colorectal Cancer Chemotherapy: The Evolution of Treatment and New Approaches.
McQuade RM; Stojanovska V; Bornstein JC; Nurgali K
Curr Med Chem; 2017; 24(15):1537-1557. PubMed ID: 28079003
[TBL] [Abstract][Full Text] [Related]
14. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
[TBL] [Abstract][Full Text] [Related]
15. Targeting the DNA damage response for patients with lymphoma: Preclinical and clinical evidences.
Carrassa L; Colombo I; Damia G; Bertoni F
Cancer Treat Rev; 2020 Nov; 90():102090. PubMed ID: 32892059
[TBL] [Abstract][Full Text] [Related]
16. Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors.
Criscuolo D; Morra F; Giannella R; Cerrato A; Celetti A
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31242618
[TBL] [Abstract][Full Text] [Related]
17. The current status of PARP inhibitors in ovarian cancer.
McLachlan J; George A; Banerjee S
Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
[TBL] [Abstract][Full Text] [Related]
18. Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers.
Przybycinski J; Nalewajska M; Marchelek-Mysliwiec M; Dziedziejko V; Pawlik A
Expert Opin Ther Targets; 2019 Sep; 23(9):773-785. PubMed ID: 31394942
[No Abstract] [Full Text] [Related]
19. [Medical treatment options in BRCA-associated cancers].
Kahán Z
Magy Onkol; 2020 Mar; 64(1):13-24. PubMed ID: 32181758
[TBL] [Abstract][Full Text] [Related]
20. Soft tissue sarcomas: new opportunity of treatment with PARP inhibitors?
Mangoni M; Sottili M; Salvatore G; Campanacci D; Scoccianti G; Beltrami G; Delli Paoli C; Dominici L; Maragna V; Olmetto E; Meattini I; Desideri I; Bonomo P; Greto D; Livi L
Radiol Med; 2019 Apr; 124(4):282-289. PubMed ID: 29582320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]